Promising rectal cancer study

A scientist comments on the evolving treatment of rectal cancer in light of findings from a study that found the immunotherapy drug dostarlimab was especially effective in a phase II clinical trial of a dozen patients with a subtype of rectal cancer.

from Top Health News -- ScienceDaily https://ift.tt/wPA07Vg